

CITATION REPORT

List of articles citing

Renal and related cardiovascular effects of conventional and COX-2-specific NSAIDs and non-NSAID analgesics

DOI: 10.1097/00045391-200007020-00004

American Journal of Therapeutics, 2000, 7, 63-74.

Source: <https://exaly.com/paper-pdf/31206855/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
135	Second-line drug therapy for osteoarthritis. 2001 , 1, 110-2; quiz 112-4		3
134	A critique of the 2000 update of the American College of Rheumatology recommendations for management of hip and knee osteoarthritis. 2001 , 44, 2451-5; author reply 2455-6		12
133	Nonnarcotic Analgesic Use and the Risk of Hypertension in US Women. 2002 , 40, 601-603		15
132	Non-steroidal anti-inflammatory drugs and antihypertensive drug therapy. 2002 , 20, 849-50		7
131	Areas of emerging interest in analgesia: cardiovascular complications. <i>American Journal of Therapeutics</i> , 2002 , 9, 259-69	1	18
130	Cyclooxygenase inhibition for postoperative analgesia. 2002 , 95, 169-76		57
129	COX-2 inhibitors and their role in gynecology. 2002 , 57, 768-80		57
128	Analgesia and the patient with osteoarthritis. <i>American Journal of Therapeutics</i> , 2002 , 9, 189-97	1	34
127	Anti-inflammatory and antipyretic analgesics and drugs used in gout. 2002 , 25, 126-138		
126	Cardiovascular risk profile of antirheumatic agents in patients with osteoarthritis and rheumatoid arthritis. 2002 , 62, 1599-609		31
125	A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents. 2002 , 18, 82-91		33
124	Tramadol/acetaminophen combination tablets for the treatment of osteoarthritis flare pain: a multicenter, outpatient, randomized, double-blind, placebo-controlled, parallel-group, add-on study. 2002 , 24, 282-97		84
123	Analysis of medication management activities for home-dwelling patients. 2002 , 59, 2356-9		5
122	Cyclooxygenase-2 inhibition and renal physiology. 2002 , 89, 10D-17D		84
121	Effects of nonsteroidal anti-inflammatory drug therapy on blood pressure and peripheral edema. 2002 , 89, 18D-25D		189
120	Nonsteroidal anti-inflammatory drugs in patients with cardio- or cerebrovascular disorders. 2003 , 92, 721-9		17
119	Evaluation of cyclooxygenase 2 inhibitor use in patients admitted to a large teaching hospital. 2003 , 33, 225-8		4

118	A model analysis of costs of blood pressure destabilization and edema associated with rofecoxib and celecoxib among older patients with osteoarthritis and hypertension in a Medicare Choice population. 2003 , 25, 647-62		7
117	Potential cardiovascular effects of COX-2 selective nonsteroidal antiinflammatory drugs. 2003 , 17, 27-50		3
116	Clinical Nephrotoxins. 2003 ,		6
115	Clinical relevance. 2003 , 3-20		6
114	Cyclooxygenase-2 inhibitors in gynecologic practice. 2003 , 1, 105-10		14
113	Resolution of drug-related problems in home care patients through a pharmacy referral service. 2003 , 60, 905-10		33
112	Pathophysiology of ischaemic acute renal failure. 2004 , 18, 21-36		42
111	Clinical perspectives of anti-inflammatory therapy in the elderly: the lipoxigenase (LOX)/cyclooxygenase (COX) inhibition concept. 2004 , 38, 201-12		35
110	Nabumetone: therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis. 2004 , 64, 2315-43; discussion 2344-5		56
109	A population-based cohort study of mortality among users of ibuprofen in Denmark. <i>American Journal of Therapeutics</i> , 2004 , 11, 156-63	1	26
108	Immunohistochemical expression of cyclooxygenase-2 in normal kidneys. 2004 , 12, 71-4		41
107	The role of paracetamol in chronic pain: an evidence-based approach. <i>American Journal of Therapeutics</i> , 2005 , 12, 80-91	1	55
106	Selecting nonprescription analgesics. <i>American Journal of Therapeutics</i> , 2005 , 12, 67-79	1	32
105	Drug-drug interactions in oncology: why are they important and can they be minimized?. 2005 , 55, 117-42		125
104	The Nonsurgical Management of Spinal Pain in the Elderly: NSAIDs, Opioids, and Epidural Steroid Injections. 2005 , 17, 144-157		
103	Urinary ET-1, AVP and sodium in premature infants treated with indomethacin and ibuprofen for patent ductus arteriosus. 2005 , 20, 1552-6		9
102	Utilisation of non-steroidal anti-inflammatory drugs (NSAIDs) through community pharmacies in Malaysia. 2005 , 17, 117-23		8
101	Drug dosing in chronic kidney disease. 2005 , 89, 649-87		60

100	Bases pharmacologiques de l'analgie multimodale. 2005 , 6, 3-7		
99	Combined lipoxygenase/cyclo-oxygenase inhibition in the elderly: the example of licofelone. 2005 , 22, 393-403		17
98	The effect of 1-furan-2-yl-3-pyridine-2-yl-propenone on pharmacokinetic parameters of theophylline. 2006 , 29, 1282-5		2
97	COX-2 Inhibitors and Cardiovascular Events: Deja Vu Du Jour. 2006 , 3, 217-221		1
96	COX-2 and the kidney. 2006 , 47 Suppl 1, S37-42		98
95	Efficacy and safety of over-the-counter analgesics in the treatment of common cold and flu. 2006 , 31, 309-19		64
94	Gastrointestinal Considerations in Patients with Cardiovascular Disease Using Nonopioid Analgesics for Mild-to-Moderate Pain or Cardioprotection. 2006 , 97, 17-22		58
93	Dehydroepiandrosterone for systemic lupus erythematosus. 2007 , CD005114		17
92	Edema in a patient receiving methadone for chronic low back pain. 2007 , 64, 2557-60		3
91	The effect of 1-furan-2-yl-3-pyridine-2-yl-propenone on pharmacokinetic parameters of warfarin. 2007 , 30, 898-904		3
90	Clinical relevance. 2008 , 3-28		1
89	Non-steroidal anti-inflammatory drugs. 2008 , 419-457		2
88	Hypertension in rheumatoid arthritis. 2008 , 47, 1286-98		197
87	Pharmacological closure of patent ductus arteriosus: effects on pulse pressure and on endothelin-1 and vasopressin excretion. 2008 , 25, 353-8		4
86	Cyclooxygenase-2 as a Target for Cancer Prevention and Treatment. 2008 , 509-541		
85	An update on cyclooxygenase-2 expression and metabolites in the kidney. 2008 , 17, 64-9		26
84	Extended-release Tramadol (ULTRAM ER): a pharmacotherapeutic, pharmacokinetic, and pharmacodynamic focus on effectiveness and safety in patients with chronic/persistent pain. <i>American Journal of Therapeutics</i> , 2008 , 15, 157-66	1	31
83	Dilemmas in chronic/persistent pain management. <i>American Journal of Therapeutics</i> , 2008 , 15, 256-64	1	26

82	Chronic pain of osteoarthritis: considerations for selecting an extended-release opioid analgesic. <i>American Journal of Therapeutics</i> , 2008 , 15, 241-55	1	13
81	The role of tramadol ER in the treatment of chronic pain. 2009 , 63, 1531-43		16
80	Sleep as a marker in the effective management of chronic osteoarthritis pain with opioid analgesics. 2010 , 39, 477-90		41
79	Celecoxib in the Treatment of Osteoarthritis. 2010 , 2, CMT.S1967		0
78	Tanezumab for the treatment of pain from osteoarthritis of the knee. 2010 , 363, 1521-31		496
77	Dilemmas in chronic/persistent pain management. 2010 , 56, 233-50		15
76	Treatment strategies for osteoarthritis patients with pain and hypertension. 2010 , 2, 229-40		14
75	ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. 2011 , 2037-114		325
74	Pharmacotherapy of low back pain: targeting nociceptive and neuropathic pain components. 2011 , 27, 11-33		88
73	ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. 2011 , 5, 259-352		100
72	Antagonism of nerve growth factor-TrkA signaling and the relief of pain. 2011 , 115, 189-204		217
71	Emerging therapies in the management of hypertensive patients with osteoarthritis. 2011 , 1, 125-136		1
70	Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized, double-blind, dose-escalation, placebo-controlled study. <i>Osteoarthritis and Cartilage</i> , 2011 , 19, 1405-12	6.2	68
69	ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. 2011 , 123, 2434-506		255
68	Effect of short-term NSAID use on echocardiographic parameters in elderly people: a population-based cohort study. 2011 , 97, 540-3		12
67	Effect of short-term NSAID use on echocardiographic parameters in elderly people: a population-based cohort study. 2012 , 2012, 412-414		
66	The role of the kidney in regulating arterial blood pressure. 2012 , 8, 602-9		76
65	Full kinetic chain manual and manipulative therapy plus exercise compared with targeted manual and manipulative therapy plus exercise for symptomatic osteoarthritis of the hip: a randomized controlled trial. 2012 , 93, 259-67		28

64	Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial. 2012 , 13, 790-8	147
63	Pharmacokinetics and pharmacodynamics of tramadol in horses following oral administration. 2013 , 36, 389-98	17
62	Nerve growth factor-mediated regulation of pain signalling and proposed new intervention strategies in clinical pain management. 2013 , 124, 276-89	101
61	Efficacy, safety, and tolerability of fulranumab, an anti-nerve growth factor antibody, in the treatment of patients with moderate to severe osteoarthritis pain. 2013 , 154, 1910-1919	81
60	Chronic low back pain: pharmacological, interventional and surgical strategies. 2013 , 9, 462-73	43
59	Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial. 2013 , 65, 1795-803	92
58	Parecoxib reduces systemic inflammation and acute lung injury in burned animals with delayed fluid resuscitation. 2014 , 2014, 972645	11
57	pH-sensitive nanoparticles of curcumin-celecoxib combination: evaluating drug synergy in ulcerative colitis model. 2014 , 103, 687-96	56
56	Parecoxib reduces renal injury in an ischemia/reperfusion model in rats. 2015 , 30, 270-6	8
55	NSAIDs and Cardiovascular Diseases: Role of Reactive Oxygen Species. 2015 , 2015, 536962	78
54	Anti-inflammatory potential of probiotic <i>Lactobacillus</i> spp. on carrageenan induced paw edema in Wistar rats. 2015 , 81, 530-7	27
53	Liquisolid technology: What it can do for NSAIDs delivery?. 2015 , 136, 185-91	11
52	Non-Steroidal Anti-Inflammatory Drugs and Chronic Kidney Disease. 2015 , 693-705	
51	Pharmacotherapeutic considerations for chronic pain in chronic kidney and end-stage renal disease. 2016 , 9, 1191-1195	9
50	Nerve Growth Factor Regulation by TNF- α and IL-1 β in Synovial Macrophages and Fibroblasts in Osteoarthritic Mice. 2016 , 2016, 5706359	42
49	COX-2 inhibitors (coxibs). 2016 , 738-762	0
48	Efficacy and Safety of Tanezumab on Osteoarthritis Knee and Hip Pains: A Meta-Analysis of Randomized Controlled Trials. <i>Pain Medicine</i> , 2017 , 18, 374-385	2.8 41
47	Efficacy and safety of fulranumab as monotherapy in patients with moderate to severe, chronic knee pain of primary osteoarthritis: a randomised, placebo- and active-controlled trial. 2016 , 70, 493-505	21

46	Gout-related inpatient utilization: a study of predictors of outcomes and time trends. 2016 , 18, 57		8
45	, the extracts of -inoculated rabbit skin, effectively alleviates the chronic low back pain with little side effect - A randomized multi-center double-blind placebo-controlled phase 3 clinical trial. 2016 , 2, 16-24		3
44	Model-based evaluation of cost-effectiveness of nerve growth factor inhibitors in knee osteoarthritis: impact of drug cost, toxicity, and means of administration. <i>Osteoarthritis and Cartilage</i> , 2016 , 24, 776-85	6.2	19
43	Screening Questions for Nonsteroidal Anti-inflammatory Drug Risk Knowledge. 2017 , 13, 217-222		2
42	[Rhinosinusitis - diagnosis and guideline-based therapy]. 2017 , 159, 37-43		
41	Nerve growth factor regulation and production by macrophages in osteoarthritic synovium. 2017 , 190, 235-243		40
40	Efficacy, tolerability, and safety of non-pharmacological therapies for chronic pain: An umbrella review on various CAM approaches. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017 , 79, 192-205	5.5	13
39	Adverse Effects and Drug Interactions of the Non-Steroidal Anti-Inflammatory Drugs. 2017 ,		3
38	Increase and regulation of synovial calcitonin gene-related peptide expression in patients with painful knee osteoarthritis. 2017 , 10, 1099-1104		15
37	Cost-effectiveness of generic celecoxib in knee osteoarthritis for average-risk patients: a model-based evaluation. <i>Osteoarthritis and Cartilage</i> , 2018 , 26, 641-650	6.2	14
36	Vitamin E and fish oil, separately or in combination, on treatment of primary dysmenorrhea: a double-blind, randomized clinical trial. 2018 , 34, 804-808		9
35	Amlodipine and celecoxib for treatment of hypertension and osteoarthritis pain. <i>Expert Review of Clinical Pharmacology</i> , 2018 , 11, 1073-1084	3.8	13
34	Investigation of chronic efficacy and safety profile of two potential anti-inflammatory bipyrazole-based compounds in experimental animals. <i>Journal of Inflammation Research</i> , 2018 , 11, 143-153	4.8	4
33	Vascular endothelial growth factor expression and their action in the synovial membranes of patients with painful knee osteoarthritis. <i>BMC Musculoskeletal Disorders</i> , 2018 , 19, 204	2.8	19
32	Reprint of: Efficacy, tolerability, and safety of non-pharmacological therapies for chronic pain: An umbrella review on various CAM approaches. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018 , 87, 307-321	5.5	1
31	Ethanollic leaf extract from <i>Strophanthus gratus</i> (Hook.) Franch. (Apocynaceae) exhibits anti-inflammatory and antioxidant activities. <i>Cogent Biology</i> , 2019 , 5, 1710431	1.6	6
30	Internalized GPCRs as Potential Therapeutic Targets for the Management of Pain. <i>Frontiers in Molecular Neuroscience</i> , 2019 , 12, 273	6.1	17
29	Lack of evidence that beta blocker use reduces knee pain, areas of joint pain, or analgesic use among individuals with symptomatic knee osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2020 , 28, 53-61	6.2	3

28	Nonsteroidal Antiinflammatory Drugs and Opioids in Chronic Kidney Disease. 2020 , 1071-1092		1
27	Enhancement of the Anti-inflammatory Effect of Bromelain by Its Immobilization on Probiotic Spore of <i>Bacillus cereus</i> . <i>Probiotics and Antimicrobial Proteins</i> , 2021 , 13, 847-861	5.5	3
26	Effects of low-dose meloxicam in cats with chronic kidney disease. <i>Journal of Feline Medicine and Surgery</i> , 2021 , 23, 138-148	2.3	8
25	Safety of Low-Dose Tanezumab in the Treatment of Hip or Knee Osteoarthritis: A Systemic Review and Meta-analysis of Randomized Phase III Clinical Trials. <i>Pain Medicine</i> , 2021 , 22, 585-595	2.8	6
24	Nonsteroidal anti-inflammatory drugs in end-stage kidney disease: dangerous or underutilized?. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 22, 769-777	4	1
23	Drug-induced peripheral oedema: An aetiology-based review. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 3043-3055	3.8	5
22	Dehydroepiandrosterone for systemic lupus erythematosus.		1
21	Non-steroidal anti-inflammatory drugs. 2003 , 279-306		4
20	Secondary Hypertension: Infrequently Considered Aspects Illicit/Recreational Substances, Herbal Remedies, and Drug-Associated Hypertension. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2018 , 723-759	0.1	1
19	Pharmacologic Management of the Orthopaedic Trauma Patient. 2009 , 253-285		1
18	Cyclooxygenase-2: from arthritis treatment to new indications for the prevention and treatment of cancer. <i>Clinical Journal of Oncology Nursing</i> , 2003 , 7, 21-9	1.1	5
17	Tanezumab for Patients with Osteoarthritis of the Knee: A Meta-Analysis. <i>PLoS ONE</i> , 2016 , 11, e0157105.7	3.7	30
16	Efficacy of Electronic Acupuncture Shoes for Chronic Low Back Pain: Double-Blinded Randomized Controlled Trial. <i>Journal of Medical Internet Research</i> , 2020 , 22, e22324	7.6	4
15	Non-steroidal anti-inflammatory drugs (NSAIDs) for colorectal cancer prevention. <i>Cancer Chemotherapy and Biological Response Modifiers</i> , 2003 , 21, 759-89		3
14	COX-2 inhibitors. 2006 , 1000-1015		
13	Sodium Balance in Heart Failure. 2007 , 351-364		
12	ADVERSE CARDIOVASCULAR EFFECTS OF NON-CARDIOVASCULAR DRUGS. 2009 , 557-820		
11	NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs). 2010 , 223-369		

10 The kidney and rheumatic disease. **2011**, 329-345.e3

9 Neurotrophins and Pain. **2014**, 1805-1823

8 Efficacy of Electronic Acupuncture Shoes for Chronic Low Back Pain: Double-Blinded Randomized Controlled Trial (Preprint).

7 Management of Hypertension in Older Patients With Arthritis. **2005**, 471-489

6 The role of tramadol in current treatment strategies for musculoskeletal pain. *Therapeutics and Clinical Risk Management*, **2007**, 3, 717-23 2.9 28

5 Physiologic and pathophysiologic roles of cyclooxygenase-2 in the kidney. *Transactions of the American Clinical and Climatological Association*, **2013**, 124, 139-51 0.9 24

4 The Role of M2000 as an Anti-inflammatory Agent in Toll-Like Receptor 2/microRNA-155 Pathway. *Avicenna Journal of Medical Biotechnology*, **2017**, 9, 8-12 1.4 8

3 Monitoring and Managing Cardiovascular Risk in Immune Mediated Inflammatory Diseases.. *Journal of Inflammation Research*, **2021**, 14, 6893-6906 4.8 1

2 ROS-Scavenging Therapeutic Hydrogels for Modulation of the Inflammatory Response.. *ACS Applied Materials & Interfaces*, **2021**, 9.5 3

1 Does anti-nerve growth factor monoclonal antibody treatment have the potential to replace nonsteroidal anti-inflammatory drugs and opioids in treating hip or knee osteoarthritis? A systematic review of randomized controlled trials. *EFORT Open Reviews*, **2022**, 7, 470-480 5.5